SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Liu CY) "

Search: WFRF:(Liu CY)

  • Result 1-10 of 221
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Ruilope, LM, et al. (author)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Journal article (peer-reviewed)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
9.
  •  
10.
  • 2021
  • swepub:Mat__t
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 221
Type of publication
journal article (209)
conference paper (7)
research review (2)
Type of content
peer-reviewed (203)
other academic/artistic (15)
Author/Editor
Kelly, S. (33)
He, X (32)
Hong, B (31)
Brenner, H (30)
Kang, JH (30)
Xie, W (30)
show more...
Gustafsson, Hans-Åke (29)
Oskarsson, Anders (29)
Jia, J. (29)
Yang, Y. (29)
Lebedev, A. (29)
Hamagaki, H. (29)
Kwon, Y. (29)
Newby, J. (29)
Oyama, K. (29)
Sugitate, T. (29)
Matsumoto, T. (29)
Belikov, S (29)
Martinez, G. (29)
Tanaka, Y. (29)
Read, KF (29)
Cianciolo, V (29)
Franz, A (29)
Homma, K (29)
Imai, K (29)
Kametani, S (29)
Kistenev, E (29)
Kotchetkov, D (29)
Kurita, K (29)
Matathias, F (29)
O'Brien, E (29)
Saito, N (29)
Sakaguchi, T (29)
Seto, R (29)
Taketani, A (29)
Velkovska, J (29)
Kikuchi, J. (29)
Ohnishi, H. (29)
Hemmick, Tk. (29)
Adler, SS (29)
Awes, TC (29)
Barish, KN (29)
Chang, WC (29)
Cole, BA (29)
Desmond, EJ (29)
Efremenko, YV (29)
Fields, DE (29)
Frawley, AD (29)
Haggerty, JS (29)
Hansen, AG (29)
show less...
University
Karolinska Institutet (189)
Lund University (55)
Uppsala University (33)
Umeå University (20)
University of Gothenburg (16)
Högskolan Dalarna (5)
show more...
Royal Institute of Technology (4)
University of Skövde (4)
Stockholm School of Economics (3)
Stockholm University (2)
Linköping University (2)
Örebro University (1)
Swedish University of Agricultural Sciences (1)
show less...
Language
English (221)
Research subject (UKÄ/SCB)
Medical and Health Sciences (59)
Natural sciences (36)
Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view